PT - JOURNAL ARTICLE AU - Grobben, Marloes AU - van der Straten, Karlijn AU - Brouwer, Philip J.M. AU - Brinkkemper, Mitch AU - Maisonnasse, Pauline AU - Dereuddre-Bosquet, Nathalie AU - Burger, Judith A. AU - Poniman, Meliawati AU - Oomen, Melissa AU - Eggink, Dirk AU - Bijl, Tom P.L. AU - van Willigen, Hugo D.G. AU - Wynberg, Elke AU - Verkaik, Bas J. AU - Figaroa, Orlane J.A. AU - de Vries, Peter J. AU - Boertien, Tessel M. AU - Grand, Roger Le AU - de Jong, Menno D. AU - Prins, Maria AU - Chung, Amy W. AU - de Bree, Godelieve J. AU - Sanders, Rogier W. AU - van Gils, Marit J. TI - Cross-reactive antibodies after SARS-CoV-2 infection and vaccination AID - 10.1101/2021.05.26.21256092 DP - 2021 Jan 01 TA - medRxiv PG - 2021.05.26.21256092 4099 - http://medrxiv.org/content/early/2021/06/18/2021.05.26.21256092.short 4100 - http://medrxiv.org/content/early/2021/06/18/2021.05.26.21256092.full AB - Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect against future novel coronavirus outbreaks, emphasizing the need for more broadly protective vaccines. To inform the development of a pan-coronavirus vaccine, we investigated the presence and specificity of cross-reactive antibodies against the spike (S) proteins of human coronaviruses (hCoV) after SARS-CoV-2 infection and vaccination. We found an 11 to 123-fold increase in antibodies binding to SARS-CoV and MERS-CoV as well as a 2 to 4-fold difference in antibodies binding to seasonal hCoVs in COVID-19 convalescent sera compared to pre-pandemic healthy donors, with the S2 subdomain of the S protein being the main target for cross-reactivity. In addition, we detected cross-reactive antibodies to all hCoV S proteins after SARS-CoV-2 S protein immunization in macaques, with higher responses for hCoV more closely related to SARS-CoV-2. These findings support the feasibility of and provide guidance for development of a pan-coronavirus vaccine.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis study is a cross-sectional observational study without intervention, it was not registered with a trial ID.Funding StatementThis work was supported by a Netherlands Organization for Scientific Research (NWO) Vici grant (to R.W.S.); by the Bill & Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery (CAVD) grants OPP1111923, OPP1132237, and INV-002022 to R.W.S.; by Health Holland PPS-allowance LSHM20040 (to M.J.v.G.) and by ZonMw (to M.D.d.J.). M.J.v.G. is a recipient of an AMC Fellowship from Amsterdam UMC and a COVID-19 grant from the Amsterdam Institute for Infection and Immunity. R.W.S and M.J.v.G. are recipients of support from the University of Amsterdam Proof of Concept fund (contract no. 200421) as managed by Innovation Exchange Amsterdam (IXA). A.W.C is supported by an NHMRC career development fellowship. The funders had no role in study design, data collection, data analysis, data interpretation, or data reporting.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For the convalescent COVID-19 sera, approval was granted by the ethical review board of the Amsterdam University Medical Centers, location AMC, the Netherlands (NL 73281.018.20) and for the healthy controls, anonymized leftover serum from routine diagnostics for which ethical approval was waived by the ethics committee of the National Institute of Public Health and the Environment was used. The study was performed in accordance with the guidelines for sharing of patient data of observational scientific research in emergency situations as issued by the Commission on Codes of Conduct of the Foundation Federation of Dutch Medical Scientific Societies (https://www.federa.org/federa-english).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData supporting the findings in this manuscript are available from the corresponding author upon request.